Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Proteomics research aids cancer diagnosis and treatment

11.04.2003


A new technique may allow physicians to monitor patients’ responses to molecularly targeted drugs, according to researchers from the National Cancer Institute (NCI) and the Food and Drug Administration (FDA) *. The finding was one of three advances in proteomics – the study of proteins within cells – scheduled to be announced by researchers from the NCI-FDA Clinical Proteomics Program in a press briefing at the 94th Annual American Association for Cancer Research (AACR) Annual Meeting, which was canceled.



Monitoring Cancer Treatment

In the first study, the researchers successfully identified specific proteins that may be useful in monitoring patients treated for breast or ovarian cancer. Their approach, based on changing levels of active proteins inside tumor cells, could help physicians determine early during treatment whether a particular drug is working effectively for an individual cancer patient.


"The results of our study suggest this approach may help us tailor treatment to individual patients," noted Virginia Espina, M.S., M.T. (ASCP), NCI, the lead investigator on the study.

Because molecularly targeted drugs are designed to target specific molecules that have gone awry in cancer cells, researchers can predict which of the cell’s many complex signaling pathways these drugs are likely to affect. In ongoing studies at NCI, researchers are using proteomic technology to monitor the key pathways likely to be influenced by the molecularly targeted drugs Gleevec®, Herceptin®, and Iressa®.

To monitor changes in tumor cell proteins, the researchers isolated cancer cells from tumor biopsies and measured the level of various proteins involved in the signaling pathways targeted by the drugs. The scientists measured not only the total amount of each protein, but also how much of the protein was in its active form. These proteins were measured prior to treatment and at selected times after treatment.

The researchers found that prior to treatment, patients with breast cancer who had a poor clinical outcome tended to have more of the active form of a protein known as AKT, which promotes cell survival. Treatment with Herceptin®, however, resulted in a change in the relative amount of the active form of AKT, enabling tumor cell death.

"Treatment with Herceptin® appears to alter the level of active AKT in tumors. We may be able to measure the degree of this change in patients who are receiving treatment to determine whether a drug that inhibits this signaling pathway is best for their individual cancer," said Lance Liotta, M.D., Ph.D., co-director of the Clinical Proteomics Program and the senior NCI investigator on the study.

The researchers expect to be able to apply the proteomic approach to monitor the treatment of other cancers with molecularly targeted drugs, but further research is required to identify the best proteins to measure in those tumors.

Diagnosing Ovarian Cancer

In another study, in collaboration with Correlogic Systems Inc., NCI and FDA scientists have improved the NCI/FDA/Correlogic method of ovarian cancer diagnosis currently under evaluation**. The approach uses Correlogic’s artificial intelligence computer programs to analyze the patterns of proteins in the blood and can detect the presence of disease even at early stages. In a previously published study, researchers used the technique to successfully differentiate between blood samples taken from patients with ovarian cancer and those from unaffected individuals.

The researchers discovered patterns of proteins that correctly identify 100 percent of blood samples as being from either unaffected individuals or patients with ovarian cancer. This is an improvement on the previous analysis, which correctly identified 100 percent of the samples from patients with cancer, but only 95 percent of the non-cancer samples. The researchers analyzed the proteins using mass spectroscopy, a technique that sorts proteins and other molecules based on their weight and electrical charge; they attribute the improvement in specificity primarily to the use of a higher resolution mass spectrometer in the most recent study. "The increased resolution allows us to distinguish more features within the patterns generated from the serum samples," said Timothy Veenstra, Ph.D., of the Mass Spectrometry Center at NCI-Frederick.

Visualizing Protein Patterns

The NCI-FDA team has also developed new tools for visualizing and analyzing protein patterns***. Beyond identifying the presence of ovarian cancer and other diseases, these tools may allow researchers to determine how far the disease has progressed by matching specific proteomic patterns to a particular stage.

"The new tools improve upon previous methods of identifying discriminatory protein patterns by allowing researchers to visualize the entire set of proteins in a single view, as well as zoom in and out to focus on regions of interest within the data," said Emanuel Petricoin III, Ph.D., co-director of the Clinical Proteomics Program and the senior FDA researcher on the project.

"Using these visualization tools, the identification of proteomic patterns that aid in disease diagnosis can be done with greater sensitivity and accuracy," said Donald Johann Jr., M.D., of the NCI-FDA Clinical Proteomics Program, lead investigator of the study. "This new method reduces the risk of error, increases our productivity, and provides an efficient method to analyze large sets of protein data.

NCI Press Office | EurekAlert!
Further information:
http://cancer.gov/cancerinfo/digestpage/proteomics
http://cancer.gov/cancerinfo/digestpage/proteomics

More articles from Health and Medicine:

nachricht Routing gene therapy directly into the brain
07.12.2017 | Boston Children's Hospital

nachricht New Hope for Cancer Therapies: Targeted Monitoring may help Improve Tumor Treatment
01.12.2017 | Berliner Institut für Gesundheitsforschung / Berlin Institute of Health (BIH)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Long-lived storage of a photonic qubit for worldwide teleportation

12.12.2017 | Physics and Astronomy

Multi-year submarine-canyon study challenges textbook theories about turbidity currents

12.12.2017 | Earth Sciences

Electromagnetic water cloak eliminates drag and wake

12.12.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>